DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce hyperglycemia in patients...

Full description

Bibliographic Details
Main Authors: Kozlovski P, Bhosekar V, Foley JE
Format: Article
Language:English
Published: Dove Medical Press 2017-03-01
Series:Vascular Health and Risk Management
Subjects:
insulin
insulin secretion rate
glucagon
alpha-cell
beta-cell
glucagon-like peptide 1
gastric inhibitory polypeptide
Online Access:https://www.dovepress.com/dpp-4-inhibitor-treatment-beta-cell-response-but-not-hba1c-reduction-i-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/dpp-4-inhibitor-treatment-beta-cell-response-but-not-hba1c-reduction-i-peer-reviewed-article-VHRM

Similar Items